What followed is an illuminating tale of how one woman's intersection with experimental research helped open a new frontier in cancer treatment - with approval of a drug that, for the first time, targets a genetic feature in a tumor rather than the ...
Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells
MONT-SAINT-GUIBERT, Belgium, May 30, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies, today announced the issuance of United ...
No comments:
Post a Comment